Comparative Pharmacology
Head-to-head clinical analysis: LESSINA 21 versus PROCOMP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LESSINA 21 versus PROCOMP.
LESSINA-21 vs PROCOMP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Suppresses gonadotropin release (FSH, LH) from pituitary, inhibiting ovulation. Causes cervical mucus thickening and endometrial alterations, impeding sperm penetration and implantation.
The combination of acetaminophen, caffeine, and isometheptene exerts its effects through multiple mechanisms: acetaminophen inhibits cyclooxygenase (COX) enzymes in the CNS, reducing prostaglandin synthesis and pain; caffeine is a non-selective adenosine receptor antagonist that enhances pain relief; isometheptene is a sympathomimetic amine that constricts dilated cerebral blood vessels.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days placebo or no tablets.
50 mg orally once daily
None Documented
None Documented
17-21 hours (terminal elimination half-life; clinical significance: allows once-daily dosing, but missed doses increase risk of ovulation)
Terminal elimination half-life: 12-18 hours (mean 15 hours). Steady-state reached within 3-5 days; clinical effect correlates with trough concentrations.
Renal (70% as unchanged drug and metabolites), fecal (30% as metabolites)
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; total recovery ~90% in urine and feces within 72 hours.
Category C
Category C
Oral Contraceptive
Oral Contraceptive